1. Home
  2. SBR vs WVE Comparison

SBR vs WVE Comparison

Compare SBR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$73.27

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$4.34

Market Cap

957.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
WVE
Founded
1982
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
957.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SBR
WVE
Price
$73.27
$4.34
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
21.8K
2.9M
Earning Date
05-14-2026
04-28-2026
Dividend Yield
6.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$85.67
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
149.43
52 Week Low
$65.31
$4.40
52 Week High
$84.39
$21.73

Technical Indicators

Market Signals
Indicator
SBR
WVE
Relative Strength Index (RSI) 46.40 30.19
Support Level $72.58 N/A
Resistance Level $76.59 $6.33
Average True Range (ATR) 1.39 0.21
MACD -0.22 -0.02
Stochastic Oscillator 18.18 1.31

Price Performance

Historical Comparison
SBR
WVE

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: